Open-label study with a single treatment arm of the multicentre, randomized study. double blind, placebo controlled, with parallel groups to compare the efficacy and safety of 0.5 mg. FTY720 administered orally once a day versus placebo with patients with progressive multiple sclerosis
Pathology and candidate patients
Dr. Luís Martí Bonmatí
Hospital Quirónsalud Valencia.
0,5 mg. FTY720
April 30, 2013
Hospital La Fe de Valencia
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the image diagnosis team by sending an email to the address: firstname.lastname@example.org